Jan 12 (Reuters) - Iovance Biotherapeutics Inc:
* IOVANCE BIOTHERAPEUTICS OBTAINS LICENSE TO DEVELOP AND COMMERCIALIZE A NOVEL IL-2 ANALOG
* OBTAINED A LICENSE FROM NOVARTIS TO DEVELOP AND COMMERCIALIZE AN ANTIBODY CYTOKINE ENGRAFTED PROTEIN, REFERRED TO AS IOV-3001
* NOVARTIS IS ALSO ENTITLED TO LOW-TO-MID SINGLE DIGIT ROYALTIES FROM COMMERCIAL SALES OF PRODUCT
* UNDER AGREEMENT, CO WILL PAY AN UPFRONT PAYMENT TO NOVARTIS AS WELL AS LOW SINGLE DIGIT MILESTONES Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.